On April 20, 2017 Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, reported that new and updated data from two ongoing clinical trials of CMB305 and G100, as well as translational data examining the association of immunological response with improved survival in CMB305 and LV305 patients, will be presented in an oral and two posters presentations at the 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, June 2 – 6, 2017 in Chicago (Press release, Immune Design, APR 20, 2017, View Source [SID1234518647]). The ASCO (Free ASCO Whitepaper) presentation details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ORAL PRESENTATION

Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS)

Abstract # 11006
Session Title: Sarcoma
Date: Friday, June 2, 2017
Time: 3 p.m. — 6 p.m. CT (oral session)
Location: S100bc
Presenter: Neeta Somaiah, M.D., Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center
POSTER PRESENTATIONS

The Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients

Abstract # 3090
Session Title: Developmental Therapeutics—Immunotherapy
Date: Monday, June 5, 2017
Time: 8 a.m. — 11:30 a.m. CT (poster session)
Location: Hall A
Presenter: Seth M. Pollack, M.D., Fred Hutchinson Cancer Research Center
Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma

Abstract # 7537
Session Title: Hematologic Malignancies — Lymphoma and Chronic Lymphocytic Leukemia
Date: Monday, June 5, 2017
Time: 8 a.m. — 11:30 a.m. CT (poster session)
Location: Hall A
Presenter: Christopher Flowers, M.D., Department of Hematology and Medical Oncology, Emory University School of Medicine
Additional data than those included in the abstracts may be included in the presentations.

On April 20, 2017 Genmab A/S (Nasdaq Copenhagen: GEN) reported that seven daratumumab abstracts have been accepted for presentation at the 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, June 2 — 6 (Press release, Genmab, APR 20, 2017, View Source [SID1234518646]). These abstracts, submitted by our collaboration partner, Janssen Biotech, Inc., include updates for the POLLUX and CASTOR trials, and the first data for a Phase I study evaluating daratumumab with carfilzomib, lenalidomide and dexamethasone in front line multiple myeloma patients, which will be presented in an oral presentation. In addition, descriptions of the Phase Ib/II study of daratumumab plus atezolizumab in non-small cell lung cancer and of our Phase I/II study with HuMax-AXL-ADC are scheduled for poster presentations at the meeting. The titles of the abstracts are currently available on the ASCO (Free ASCO Whitepaper) website with the full abstracts scheduled to be published on May 17, 2017.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very pleased that, once again, a number of abstracts based on exciting work with Genmab’s innovative therapeutic antibody products have been accepted for presentation at the prestigious ASCO (Free ASCO Whitepaper) conference," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

List of abstracts:
Daratumumab:
Efficacy Of Daratumumab In Combination with Lenalidomide Plus Dexamethasone (DRd) or Bortezomib Plus Dexamethasone (DVd) in Relapsed or Refractory Multiple Myeloma Based on Cytogenic Risk Status — Oral presentation, Sunday, June 4, 11:45 AM — 11:57 AM CDT

Daratumumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma: An Open-Label, Phase Ib Study — Oral presentation, Sunday, June 4, 9:45 AM — 9:57 AM CDT

Safety and Efficacy of Daratumumab-based Regimens in Elderly (≥75 years) Patients with Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of POLLUX and CASTOR — Poster presentation, Monday, June 5, 8:00 AM — 11:30 AM CDT

Daratumumab, Lenalidomide and Dexamethasone (DRd) versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety Update (POLLUX) — Poster presentation, Monday, June 5, 8:00 AM — 11:30 AM CDT

Daratumumab, Bortezomib and Dexamethasone (DVd) versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety Update (CASTOR) — Poster presentation, Monday, June 5, 8:00 AM — 11:30 AM CDT

Randomized, Open-label Phase Ib/II Study of Atezolizumab with or without Daratumumab in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer — Trials in Progress Poster presentation, Saturday, June 3, 8:00 AM — 11:30 AM CDT

Comparative Efficacy of Multiple Myeloma Therapies for Treatment of First Relapse — A Systematic Literature Review and Network Meta-analysis — Poster presentation, Monday, June 5, 8:00 AM — 11:30 AM CDT

HuMax-AXL-ADC:
GCT1021-01, a First-in-Human, Open-Label, Dose-Escalation Trial with Expansion Cohorts to evaluate Safety of Axl-Specific Antibody-Drug Conjugate (HuMax-AXL-ADC) in Patients with Solid Tumors — Trials in Progress Poster presentation, Monday, June 5, 8:00 AM — 11:30 AM CDT

On April 20, 2017 Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, reported that it will feature two clinical poster presentations during the 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, being held June 2-6, in Chicago (Press release, Five Prime Therapeutics, APR 20, 2017, View Source [SID1234518645]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Number and Title: #4067, "Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b+ gastric cancer"
Poster Session: Gastrointestinal (Noncolorectal) Cancer
Session Date and Time: Saturday, June 3, 2017, 8 – 11:30 a.m.
Location: Hall A, Poster Board Number: 59

Abstract Number and Title: #11078, "A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS)"
Poster Session: Sarcoma
Session Date and Time: Sunday, June 4, 2017, 8 – 11:30 a.m.
Location: Hall A, Poster Board Number: 401

On April 20, 2017 Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, reported that the Company will release its first quarter 2017 financial results on Monday, May 8, 2017 (Press release, Epizyme, APR 20, 2017, View Source [SID1234518644]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Epizyme also announced that two posters on interim efficacy and safety data from its ongoing Phase 2 study of tazemetostat in adult patients with molecularly defined solid tumor will be presented on June 6, 2017 at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago. The Company plans to hold a conference call to discuss the interim findings on Thursday, May 18, 2017 at 8:30 a.m. ET, after the ASCO (Free ASCO Whitepaper) abstracts have been released.

Considering the planned conference call, Epizyme will not host a separate conference call to discuss its first quarter 2017 financial results.

The Phase 2 data posters will be presented in the ASCO (Free ASCO Whitepaper) session listed below:

Sarcoma Cancer: General Poster Session
Sunday, June 4, 2017, 8:00 a.m. – 11:30 a.m. CDT
Abstract No.: 11058, Poster Board No.: 381
Title: Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950)
Location: Hall A

Sarcoma Cancer: General Poster Session
Sunday, June 4, 2017, 8:00 a.m. – 11:30 a.m. CDT
Abstract No.: 11057, Poster Board No.: 380
Title: Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma (NCT02601950)
Location: Hall A

About the Tazemetostat Clinical Trial Program
Tazemetostat, a first-in-class EZH2 inhibitor, is currently being studied in ongoing phase 2 programs in non-Hodgkin lymphoma (NHL), certain genetically defined solid tumors, including INI1-negative and SMARCA4-negative tumors and synovial sarcoma, and mesothelioma.

On April 20, 2017 Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, reported that clinical data for its drug candidate CB-1158, an orally bioavailable arginase inhibitor, will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), which is being held from June 2 to June 6, 2017 in Chicago, Illinois (Press release, Calithera Biosciences, APR 20, 2017, View Source [SID1234518643]). Clinical results to be presented include monotherapy data from Calithera’s Phase I trial in solid tumors. CB-1158 is being developed in collaboration with Incyte Corporation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CX-1158-101: A first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients with solid tumors.
Abstract #3005
Presenter: Kyriakos Papadopoulos MD, South Texas Accelerated Research Therapeutics
Date: June 5, 2017
Session: 1:15 p.m. – 4:15 p.m. CT, Developmental Therapeutics-Immunology, Hall D1